LON:IXIIxico Share Price, Forecast & News

GBX 68.85

-0.15 (-0.22 %)

(As of 05/29/2020 04:38 AM ET)

Add

Compare

Today's Range

68.85

Now: GBX 68.85▼

68.85

50-Day Range

57.88

MA: GBX 66.13▼

52-Week Range

25.66

Now: GBX 68.85▼

Volume2,914 shs

Average Volume2,474 shs

Market Capitalization£32.42 million

P/E Ratio45.90

Dividend YieldN/A

BetaN/A

IXICO plc provides technology enabled services to the biopharmaceutical industry worldwide. The company's technologies include Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, QC, and reading/analysis to reporting and data transfer. The company offers end-to-end imaging services, primarily in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases; and engages in the data collection and analysis of neurological diseases. Its services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development, and in post marketing surveillance. The company was incorporated in 1995 and is based in London, the United Kingdom.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Ixico.

2.7 Community Rank

Outperform Votes
Ixico has received 139 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ixico has received 114 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ixico has received 54.94% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ixico and other stocks. Vote “Outperform” if you believe IXI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IXI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ixico does not currently pay a dividend.
Dividend Growth
Ixico does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ixico insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Ixico are expected to grow in the coming year, from GBX (1.20) to GBX 0 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ixico is 45.90, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.91.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ixico is 45.90, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.38.
Price to Book Value per Share Ratio
Ixico has a P/B Ratio of 3.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.67 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolLON:IXI

Previous Symbol

CUSIPN/A

CIKN/A

Webixico.com

Phone+44-20-37637499

Debt

Debt-to-Equity RatioN/A

Current Ratio5.01

Quick Ratio5.01

Price-To-Earnings

Trailing P/E Ratio45.90

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales£8.69 million

Price / Sales3.73

Cash FlowGBX 14.17 per share

Price / Cash Flow4.86

Book ValueGBX 18.10 per share

Price / Book3.80

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees67

Outstanding Shares47,091,300

Market Cap£32.42 million

Next Earnings DateN/A

OptionableNot Optionable

Receive IXI News and Ratings via Email

Sign-up to receive the latest news and ratings for IXI and its competitors with MarketBeat's FREE daily newsletter.

Ixico (LON:IXI) Frequently Asked Questions

How has Ixico's stock been impacted by COVID-19 (Coronavirus)?

Ixico's stock was trading at GBX 57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IXI stock has increased by 20.8% and is now trading at GBX 68.85. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ixico?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ixico in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ixico.

How were Ixico's earnings last quarter?

Ixico Plc (LON:IXI) announced its quarterly earnings results on Wednesday, May, 20th. The company reported $1.01 EPS for the quarter. View Ixico's earnings history.

Has Ixico been receiving favorable news coverage?

News headlines about IXI stock have trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ixico earned a news impact score of -3.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutIxico.

Who are some of Ixico's key competitors?

Some companies that are related to Ixico include CorMedix (CRMD), Verseon (VSN), Lineage Cell Therapeutics (LCTX), MediGene (MDG1), Senesco Technologies (ELOX), CorMedix (CRMD), Predictive Technology Group (PRED), Cohbar (CWBR), 22nd Century Group (XXII), Ampliphi Biosciences (APHB), Altimmune (ALT), iShares Diversified Alternatives Trust (ALT), Ibio (IBIO), Ampio Pharmaceuticals (AMPE) and Circassia Pharmaceuticals (CIR). View all competitors.

What other stocks do shareholders of Ixico own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ixico investors own include Motif Bio (MTFB), ReNeuron Group (RENE), Pendragon (PDG), Enquest (ENQ) and Chariot Oil & Gas (CHAR).

Who are Ixico's key executives?

Ixico's management team includes the following people:

Mr. Giulio Cerroni, CEO & Director (Age 57)
Prof. Derek Lionel Glendon Hill, Co-Founder and Pres of Regulatory Science & External Relations (Age 53)
Prof. Daniel Rueckert, Co-Founder & Member of Scientific Advisory Board
Prof. David Hawkes, Co-Founder & Member of Scientific Advisory Board
Prof. Joseph Hajnal, Co-Founder & Member of Scientific Advisory Board

What is Ixico's stock symbol?

Ixico trades on the London Stock Exchange (LON) under the ticker symbol "IXI."

How do I buy shares of Ixico?

Shares of IXI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Ixico's stock price today?

One share of IXI stock can currently be purchased for approximately GBX 68.85.

How big of a company is Ixico?

Ixico has a market capitalization of £32.42 million and generates £8.69 million in revenue each year. Ixico employs 67 workers across the globe.

What is Ixico's official website?

The official website for Ixico is ixico.com.

How can I contact Ixico?

Ixico's mailing address is 4th Fl, Griffin Court, 15 Long Lane, LONDON, EC1A 9PN, United Kingdom. The company can be reached via phone at +44-20-37637499.

This page was last updated on 5/29/2020 by MarketBeat.com Staff